Home / Knowledge Center /
Poster

DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

Ovarian cancer is the leading cause of death from gynecological malignancies. The standard first line therapy is a combination of carboplatin and paclitaxel and has a response rate of 70%-80%, although the majority relapse. Almac have previously developed a 44 transcript DNA damage response deficiency (DDRD) assay which indicates loss of the FA/BRCA pathway and predicts response to DNA damaging agents. In this study we have investigated the utility of the DDRD assay predicting response to platinum based therapy in ovarian cancer.

View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialization.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialization services.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies